# US 2009/0280163 A1 · High-Efficiency Fusogenic Vesicles, Methods of Producing Them, and Pharmaceutical Compositions Containing Them

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0280163 A1
- Document ID: US20090280163A1
- Status: Published application
- Kind: A1
- Application number: 12/029,454
- Filed: 2008-02-11
- Published: 2009-11-12
- Earliest claimed: 2002-11-21
- Assignees: Pevion Biotech Ltd.
- Inventors: Sonia Vadrucci; Joseph Brunner; Rinaldo Zubriggen
- Web page: https://patentgrep.com/patent/US20090280163A1

## CPC

- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- Y10S 977/799: Containing biological material
- Y10S 977/80: Nucleic acid, e.g. DNA or RNA
- Y10S 977/801: Drug
- Y10S 977/802: Virus-based particle
- Y10S 977/803: Containing biological material in its interior
- Y10S 977/804: Containing nucleic acid
- Y10S 977/805: Containing drug
- Y10S 977/808: Exterior attachment for targeting, e.g. drug targeting
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present invention relates to novel fusogenic vesicles as highly efficient and versatile encapsulation systems for delivering a substance of choice, such as nucleic acids, proteins, peptides, antigens, pharmaceutical drugs and cosmetic agents to cells and tissues.

## Claims

### Claim at position 1

1-38. (canceled)

### Claim 39

A fusogenic vesicle encapsulating at least one therapeutic or immunologically active substance, said fusogenic vesicle comprising a first viral fusion protein derived from influenza virus and a second viral fusion protein derived from influenza virus wherein the second viral fusion protein is capable of causing fusion at a different temperature or a different pH than the first viral fusion protein.

### Claim 40 (depends on 39)

The fusogenic vesicle according to claim 39, wherein the first viral fusion protein is inactivated.

### Claim 41 (depends on 40)

The fusogenic vesicle according to claim 40, wherein the second viral fusion protein is fusion competent.

### Claim 42 (depends on 39)

The fusogenic vesicle according to claim 39, wherein the vesicle is unilamellar.

### Claim 43 (depends on 39)

The fusogenic vesicle according to claim 39, wherein the at least one therapeutic or immunologically active substance is selected from the group consisting of DNA, RNA, and siRNA.

### Claim 44 (depends on 39)

The fusogenic vesicle according to claim 39, wherein the at least one therapeutic or immunologically active substance is selected from the group consisting of proteins, peptides, amino acids and pharmaceutically active substances.

### Claim 45 (depends on 39)

The fusogenic vesicle according to claim 39, wherein the at least one therapeutic or immunologically active substance is selected from the group consisting of a cosmetic agent, a pharmaceutical drug, an antigen or mixtures thereof.

### Claim 46 (depends on 39)

The fusogenic vesicle according to claim 39, wherein at least one of the first viral fusion protein or second viral fusion protein is cell type specific.

### Claim 47 (depends on 39)

The fusogenic vesicle according to claim 39, wherein at least one of the first viral fusion protein or second viral fusion protein is selected from the group consisting of PR8/34 and A/Singapore HA.

### Claim 48 (depends on 39)

The fusogenic vesicle according to claim 39, further comprising lipids derived from the group consisting of glycolipids, phospholipids, cationic lipids, synthetic lipids and cholesterol.

### Claim 49 (depends on 48)

The fusogenic vesicle according to claim 48, wherein the lipids comprise POPC and DDAB.

### Claim 50 (depends on 48)

The fusogenic vesicle according to claim 48, wherein the lipids are derived from influenza virus.

### Claim 51 (depends on 39)

The fusogenic vesicle according to claim 39, wherein the vesicle has a diameter of between 100 and 300 nm.

### Claim 52 (depends on 39)

The fusogenic vesicle according to claim 39, further comprising a cell-surface receptor, cytokine, growth-factor, antibody, or antibody fragment.

### Claim 53

A method for preparing a fusogenic vesicle comprising fusing a chimeric virosome, wherein the chimeric virosome comprises a first viral fusion protein derived from influenza virus and a second viral fusion protein derived from influenza virus wherein the second viral fusion protein is capable of causing fusion at a different temperature or a different pH than the first viral fusion protein, with a liposome, wherein the liposome encapsulates at least one therapeutic or immunologically active substance to form the fusogenic vesicle.

### Claim 54 (depends on 53)

The method of claim 53, further comprising encapsulating at least one therapeutic or immunologically active substance within a liposome.

### Claim 55 (depends on 53)

The method of claim 53, further comprising preparing the chimeric virosome by combining the first viral fusion protein and the second viral fusion protein.

### Claim 56 (depends on 53)

The method of claim 53 further comprising adjusting the size of the fusogenic vesicle such that the fusogenic vesicle has a diameter of between 100 and 300 nm.

### Claim 57 (depends on 53)

A fusogenic vesicle produced by the method of claim 53.

### Claim 58

A chimeric virosome comprising a first viral fusion protein derived from influenza virus and a second viral fusion protein derived from influenza virus wherein the second viral fusion protein is capable of causing fusion at a different temperature or a different pH than the first viral fusion protein.

### Claim 59 (depends on 58)

The chimeric virosome according to claim 58 capable of undergoing sequential and separate fusion events.
